On Mar. 3, 2021, Altasciences announced support for ReAlta Life Sciences’ Phase I trial to evaluate RLS-0071 for treatment of Acute Lung Injury (ALI) as a result of viral infections, such as COVID-19, respiratory syncytial virus (RSV), and influenza.

As part of the ReAlta ALI program underway, the Phase I trial was a single-ascending dose, randomized, double-blind, placebo-controlled, adaptive-design study to evaluate the safety, tolerability, PK, and PD of RLS-0071 in healthy subjects, performed at the Altasciences clinical pharmacology unit in Montreal, Canada.